Kintara Therapeutics Stock Beta
| KTRADelisted Stock | USD 6.30 0.14 2.17% |
Kintara Therapeutics fundamentals help investors to digest information that contributes to Kintara Therapeutics' financial success or failures. It also enables traders to predict the movement of Kintara Stock. The fundamental analysis module provides a way to measure Kintara Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kintara Therapeutics stock.
Kintara |
Kintara Therapeutics Company Beta Analysis
Kintara Therapeutics' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Kintara Therapeutics Beta | 0.81 |
Most of Kintara Therapeutics' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kintara Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, Kintara Therapeutics has a Beta of 0.812. This is 5.58% lower than that of the Biotechnology sector and 41.58% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Kintara Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kintara Therapeutics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kintara Therapeutics could also be used in its relative valuation, which is a method of valuing Kintara Therapeutics by comparing valuation metrics of similar companies.Kintara Therapeutics is currently under evaluation in beta category among its peers.
As returns on the market increase, Kintara Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Kintara Therapeutics is expected to be smaller as well.
Kintara Fundamentals
| Return On Equity | -3.71 | |||
| Return On Asset | -1.04 | |||
| Current Valuation | 17.98 M | |||
| Shares Outstanding | 55.66 M | |||
| Shares Owned By Insiders | 0.12 % | |||
| Shares Owned By Institutions | 1.47 % | |||
| Number Of Shares Shorted | 5.43 M | |||
| Price To Book | 7.81 X | |||
| EBITDA | (8.5 M) | |||
| Net Income | (8.32 M) | |||
| Cash And Equivalents | 11.78 M | |||
| Cash Per Share | 0.15 X | |||
| Total Debt | 2.44 M | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 3.32 X | |||
| Book Value Per Share | (0.12) X | |||
| Cash Flow From Operations | (7.18 M) | |||
| Short Ratio | 1.14 X | |||
| Earnings Per Share | (11.20) X | |||
| Target Price | 14.0 | |||
| Beta | 0.81 | |||
| Market Capitalization | 11.99 M | |||
| Total Asset | 6.2 M | |||
| Retained Earnings | (159.88 M) | |||
| Working Capital | 188 K | |||
| Net Asset | 6.2 M |
About Kintara Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kintara Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kintara Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kintara Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Other Consideration for investing in Kintara Stock
If you are still planning to invest in Kintara Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kintara Therapeutics' history and understand the potential risks before investing.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |